Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Degron Therapeutics Inc.
BioCentury | Oct 31, 2024
Deals
Trend watch: Degrader deals show glues are sticking
At least seven molecular glue degrader deals announced this year; less deal activity for classical PROTACs
BioCentury | May 29, 2024
Deals
Deals Report: Three $1B+ takeouts highlight demand in immunology, renal
Plus: Takeda-Degron to develop molecular glue degraders; Lilly-Aktis collaborate on radiopharmaceuticals; and more
BioCentury | May 23, 2024
Product Development
Amphista degrades a cancer target using a non-traditional ligase
Amphista’s targeted glues combine the advantages of PROTACs and molecular glues to create selective, orally bioavailable therapies
BioCentury | Nov 11, 2022
Product Development
Molecular glue degraders: moving beyond IMiDs
Technologies unraveling the relationships between glue structures and conformational changes are opening up new targets and E3 ligases
BioCentury | Jun 10, 2022
Finance
June 9 Quick Takes: Venture rounds for Tessa, Degron, Ancora, Charm and Relation
Plus Arnay partners with Alloy and updates from DBV and more
Items per page:
1 - 5 of 5